Cotinga Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cotinga Pharmaceuticals Inc.
SVP Elliott Levy said the company hasn't ruled out a tumor-agnostic approach for AMG 510, but Phase I data for the first-in-class drug show a bigger effect in lung cancer – a 50% response rate, so far – than in colorectal cancer patients with a KRAS G12C mutation.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
START-UP’s monthly update on technology transfer deals—licensing agreements between companies and universities or other research institutions—in in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies.
Drug Discovery Tools
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Critical Outcome Technologies Inc.